The Role of Endogenous Neurotensin in Psychostimulant-induced Disruption of Prepulse Inhibition and Locomotion

Overview

Journal Schizophr Res

Specialty Psychiatry

Date 2011 Nov 23

PMID 22104138

Citations 6

Authors

Ricardo Caceda

Elisabeth B Binder

Becky Kinkead

Charles B Nemeroff

Affiliations

Soon will be listed here.

Abstract

The neuropeptide neurotensin (NT) is closely associated with dopaminergic and glutamatergic systems in the rat brain. Central injection of NT into the nucleus accumbens (NAcc) or peripheral administration of NT receptor agonists, reduces many of the behavioral effects of psychostimulants. However, the role of endogenous NT in the behavioral effects of psychostimulants (e.g. DA agonists and NMDA receptor antagonists) remains unclear. Using a NTR antagonist, SR142948A, the current studies were designed to examine the role of endogenous NT in DA receptor agonist- and NMDA receptor antagonist-induced disruption of prepulse inhibition of the acoustic startle response (PPI), locomotor hyperactivity and brain-region specific c-fos mRNA expression. Adult male rats received a single i.p. injection of SR142948A or vehicle followed by D-amphetamine, apomorphine or dizocilpine challenge. SR142948A had no effect on baseline PPI, but dose-dependently attenuated d-amphetamine- and dizocilpine-induced PPI disruption and enhanced apomorphine-induced PPI disruption. SR142948A did not significantly affect either baseline locomotor activity or stimulant-induced hyperlocomotion. Systemic SR142948A administration prevented c-fos mRNA induction in mesolimbic terminal fields (prefrontal cortex, lateral septum, NAcc, ventral subiculum) induced by all three psychostimulants implicating the VTA as the site for NT modulation of stimulant-induced PPI disruption. Further characterization of the NT system may be valuable to find clinical useful compounds for schizophrenia and drug addiction.

Citing Articles

The Atypical Dopamine Transporter Inhibitor CE-158 Enhances Dopamine Neurotransmission in the Prefrontal Cortex of Male Rats: A Behavioral, Electrophysiological, and Microdialysis Study.

Sagheddu C, Cancedda E, Bagheri F, Kalaba P, Muntoni A, Lubec J Int J Neuropsychopharmacol. 2023; 26(11):784-795.

PMID: 37725477 PMC: 10674083. DOI: 10.1093/ijnp/pyad056.

Determination of neurotensin projections to the ventral tegmental area in mice.

Woodworth H, Brown J, Batchelor H, Bugescu R, Leinninger G Neuropeptides. 2018; 68:57-74.

PMID: 29478718 PMC: 5906039. DOI: 10.1016/j.npep.2018.02.003.

Antagonism of Neurotensin Receptors in the Ventral Tegmental Area Decreases Methamphetamine Self-Administration and Methamphetamine Seeking in Mice.

Dominguez-Lopez S, Piccart E, Lynch W, Wollet M, Sharpe A, Beckstead M Int J Neuropsychopharmacol. 2017; 21(4):361-370.

PMID: 29272412 PMC: 5888879. DOI: 10.1093/ijnp/pyx117.

ML314: A Biased Neurotensin Receptor Ligand for Methamphetamine Abuse.

Barak L, Bai Y, Peterson S, Evron T, Urs N, Peddibhotla S ACS Chem Biol. 2016; 11(7):1880-90.

PMID: 27119457 PMC: 4947017. DOI: 10.1021/acschembio.6b00291.

Synaptic Cytoskeletal Plasticity in the Prefrontal Cortex Following Psychostimulant Exposure.

DePoy L, Gourley S Traffic. 2015; 16(9):919-40.

PMID: 25951902 PMC: 4849269. DOI: 10.1111/tra.12295.

References

Nouel D, Dubuc I, Kitabgi P, Costentin J . Centrally administered [D-Trp11]neurotensin, as well as neurotensin protected from inactivation by thiorphan, modifies locomotion in rats in a biphasic manner. Peptides. 1990; 11(3):551-5. DOI: 10.1016/0196-9781(90)90058-d. View

Carlsson A . The neurochemical circuitry of schizophrenia. Pharmacopsychiatry. 2006; 39 Suppl 1:S10-4. DOI: 10.1055/s-2006-931483. View

Fujimura M, Hashimoto K, Yamagami K . Effects of antipsychotic drugs on neurotoxicity, expression of fos-like protein and c-fos mRNA in the retrosplenial cortex after administration of dizocilpine. Eur J Pharmacol. 2000; 398(1):1-10. DOI: 10.1016/s0014-2999(00)00235-1. View

Feifel D, Reza T . Oxytocin modulates psychotomimetic-induced deficits in sensorimotor gating. Psychopharmacology (Berl). 1999; 141(1):93-8. DOI: 10.1007/s002130050811. View

Harvey J, Lacey M . A postsynaptic interaction between dopamine D1 and NMDA receptors promotes presynaptic inhibition in the rat nucleus accumbens via adenosine release. J Neurosci. 1997; 17(14):5271-80. PMC: 6793812. View

Kalivas P, Burgess S, Nemeroff C, Prange Jr A . Behavioral and neurochemical effects of neurotensin microinjection into the ventral tegmental area of the rat. Neuroscience. 1983; 8(3):495-505. DOI: 10.1016/0306-4522(83)90195-1. View

Feifel D, Pang Z, Shilling P, Melendez G, Schreiber R, Button D . Sensorimotor gating in neurotensin-1 receptor null mice. Neuropharmacology. 2009; 58(1):173-8. PMC: 2784210. DOI: 10.1016/j.neuropharm.2009.07.002. View

Gully D, Jeanjean F, Poncelet M, Steinberg R, Soubrie P, Le Fur G . Neuropharmacological profile of non-peptide neurotensin antagonists. Fundam Clin Pharmacol. 1995; 9(6):513-21. DOI: 10.1111/j.1472-8206.1995.tb00528.x. View

Feifel D, Reza T . Effects of neurotensin administered into the ventral tegmental area on prepulse inhibition of startle. Behav Brain Res. 1999; 106(1-2):189-93. DOI: 10.1016/s0166-4328(99)00123-0. View

10.

Gao X, Hashimoto T, Tamminga C . Phencyclidine (PCP) and dizocilpine (MK801) exert time-dependent effects on the expression of immediate early genes in rat brain. Synapse. 1998; 29(1):14-28. DOI: 10.1002/(SICI)1098-2396(199805)29:1<14::AID-SYN2>3.0.CO;2-E. View

11.

Binder E, Kinkead B, Owens M, Nemeroff C . Neurotensin and dopamine interactions. Pharmacol Rev. 2001; 53(4):453-86. View

12.

During M, Bean A, Roth R . Effects of CNS stimulants on the in vivo release of the colocalized transmitters, dopamine and neurotensin, from rat prefrontal cortex. Neurosci Lett. 1992; 140(1):129-33. DOI: 10.1016/0304-3940(92)90698-7. View

13.

Pennartz C, Groenewegen H, Lopes da Silva F . The nucleus accumbens as a complex of functionally distinct neuronal ensembles: an integration of behavioural, electrophysiological and anatomical data. Prog Neurobiol. 1994; 42(6):719-61. DOI: 10.1016/0301-0082(94)90025-6. View

14.

Jaber M, Cador M, Dumartin B, Normand E, Stinus L, Bloch B . Acute and chronic amphetamine treatments differently regulate neuropeptide messenger RNA levels and Fos immunoreactivity in rat striatal neurons. Neuroscience. 1995; 65(4):1041-50. DOI: 10.1016/0306-4522(94)00537-f. View

15.

Poncelet M, Souilhac J, Gueudet C, Terranova J, Gully D, Le Fur G . Effects of SR 48692, a selective non-peptide neurotensin receptor antagonist, on two dopamine-dependent behavioural responses in mice and rats. Psychopharmacology (Berl). 1994; 116(2):237-41. DOI: 10.1007/BF02245067. View

16.

Panegyres P, Hughes J . Activation of c-fos mRNA in the brain by the kappa-opioid receptor agonist enadoline and the NMDA receptor antagonist dizocilpine. Eur J Pharmacol. 1997; 328(1):31-6. DOI: 10.1016/s0014-2999(97)83023-3. View

17.

Marie-Claire C, Palminteri S, Romualdi P, Noble F . Effects of the selective neurotensin antagonist SR 142948A on 3,4-methylenedioxymethamphetamine-induced behaviours in mice. Neuropharmacology. 2008; 54(7):1107-11. DOI: 10.1016/j.neuropharm.2008.03.001. View

18.

Sills T . Amphetamine dose dependently disrupts prepulse inhibition of the acoustic startle response in rats within a narrow time window. Brain Res Bull. 1999; 48(4):445-8. DOI: 10.1016/s0361-9230(99)00036-2. View

19.

Paul M, Currie R, Robertson H . Priming of a D1 dopamine receptor behavioural response is dissociated from striatal immediate-early gene activity. Neuroscience. 1995; 66(2):347-59. DOI: 10.1016/0306-4522(94)00582-p. View

20.

Casti P, Marchese G, Casu G, Ruiu S, Pani L . Blockade of neurotensin receptors affects differently hypo-locomotion and catalepsy induced by haloperidol in mice. Neuropharmacology. 2004; 47(1):128-35. DOI: 10.1016/j.neuropharm.2004.03.001. View